[HTML][HTML] Risk factors and preventions of breast cancer
YS Sun, Z Zhao, ZN Yang, F Xu, HJ Lu… - … journal of biological …, 2017 - ncbi.nlm.nih.gov
Breast cancer is the second leading cause of cancer deaths among women. The
development of breast cancer is a multi-step process involving multiple cell types, and its …
development of breast cancer is a multi-step process involving multiple cell types, and its …
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
J Wang, B Xu - Signal transduction and targeted therapy, 2019 - nature.com
Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …
[HTML][HTML] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G Curigliano, D Lenihan, M Fradley, S Ganatra… - Annals of …, 2020 - Elsevier
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …
world. Evidence increasingly shows that these conditions are interlinked through common …
A landscape of response to drug combinations in non-small cell lung cancer
Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited
efficacy of single agents. The design and testing of combinations are however very …
efficacy of single agents. The design and testing of combinations are however very …
[HTML][HTML] Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 …
M Riudavets, I Sullivan, P Abdayem, D Planchard - ESMO open, 2021 - Elsevier
Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …
NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for …
L Fehrenbacher, RS Cecchini, CE Geyer Jr… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk
for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the …
for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the …
Metastatic and triple-negative breast cancer: challenges and treatment options
S Al-Mahmood, J Sapiezynski, OB Garbuzenko… - Drug delivery and …, 2018 - Springer
The major current conventional types of metastatic breast cancer (MBC) treatments include
surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing …
surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing …
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis …
V Diéras, D Miles, S Verma, M Pegram… - The Lancet …, 2017 - thelancet.com
Background The antibody–drug conjugate trastuzumab emtansine is indicated for the
treatment of patients with HER2-positive metastatic breast cancer previously treated with …
treatment of patients with HER2-positive metastatic breast cancer previously treated with …
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
SM Swain, J Baselga, SB Kim, J Ro… - New England journal …, 2015 - Mass Medical Soc
Background In patients with metastatic breast cancer that is positive for human epidermal
growth factor receptor 2 (HER2), progression-free survival was significantly improved after …
growth factor receptor 2 (HER2), progression-free survival was significantly improved after …
[HTML][HTML] Targeted therapy for breast cancer: An overview of drug classes and outcomes
AT Jacobs, DM Castaneda-Cruz, MM Rose… - Biochemical …, 2022 - Elsevier
The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …
termed targeted therapies based on their ability to block specific pathways known to drive …